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Adjuvants in Veterinary Vaccines: Modes of Action
and Adverse Effects
Anna R. Spickler and James A. Roth
Vaccine adjuvants are chemicals, microbial components, or mammalian proteins that enhance the immune response to vaccine
antigens. Interest in reducing vaccine-related adverse effects and inducing specific types of immunity has led to the development
of numerous new adjuvants. Adjuvants in development or in experimental and commercial vaccines include aluminum salts (alum),
oil emulsions, saponins, immune-stimulating complexes (ISCOMs), liposomes, microparticles, nonionic block copolymers, deriv-
atized polysaccharides, cytokines, and a wide variety of bacterial derivatives. The mechanisms of action of these diverse compounds
vary, as does their induction of cell-mediated and antibody responses. Factors influencing the selection of an adjuvant include
animal species, specific pathogen, vaccine antigen, route of immunization, and type of immunity needed.
Key words: Enhancement of immunity; Immunization; Immunomodulation.
The advent of vaccination in the 1800s had unprece-dented benefits for both human and veterinary med-
icine. Vaccines now control or prevent numerous human
and animal diseases, including scourges such as poliomy-
elitis, smallpox, distemper, and parvovirus enteritis. The
contributions of pioneer vaccine researchers such as Pasteur
and Jenner are well known. Less often noted are parallel
discoveries that made vaccination more powerful and, in-
deed, in some cases, even feasible. In the 1920s, Ramon1,2
discovered that horses that developed abscesses at the in-
jection site had higher antibody titers after vaccination.
Subsequently, he and others found that titers could be en-
hanced by injections of tapioca, agar, lecithin, saponin, and
aluminum compounds.2,3 In the 1930s, Freund et al4 in-
vented a particularly effective combination of mineral oil,
water, and killed mycobacteria. These discoveries were the
basis for the development of adjuvants, vaccine additives
that boost immunity and alter immune responses to coad-
ministered antigens.
A protective immune response must enhance those as-
pects of immunity that will be effective against specific
pathogens. Vaccines against extracellular bacteria should
induce immunoglobulin G (IgG) to opsonize the bacteria
for phagocytosis, to activate complement, and to neutralize
toxins. On mucosal surfaces, IgA prevents attachment, and
IgE arms mast cells under the mucosal surface to react if
the pathogen invades. Other pathogens are effectively de-
stroyed only by cell-mediated immune reactions. For fac-
ultative intracellular bacteria (eg, Mycobacteria, Brucella,
and some Salmonella), activated macrophages are required.
If a pathogen such as a virus, Listeria, or some protozoan
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parasite begins to replicate in the cytoplasm of a cell, a
cytotoxic T-lymphocyte (CTL) response is needed to de-
stroy the infected cell. Often, a combination of immune
mechanisms may be the most effective defense: for exam-
ple, an IgA response to inhibit viruses from invading
through a mucosal surface, an IgG response to neutralize
viruses that do invade, and a cytotoxic T-cell response to
destroy cells that the virus manages to infect.
Infection with a virulent pathogen usually provides the
necessary signals to induce the correct type or types of
immune response. By mimicking the virulent organism,
modified live vaccines also can provide these signals. Al-
though they often are very effective, these vaccines have
several potential disadvantages and are undesirable for
some diseases.5 The main alternative at present is a killed
vaccine. However, killed vaccine antigens administered by
an unnatural route of exposure (ie, injection) may not pro-
vide the signals necessary to induce protective immunity.
Less purified killed vaccines sometimes contain bacterial or
viral components that can serve as ‘‘built-in’’ adjuvants, but
more purified antigens usually do not stimulate a strong and
lasting immune response.6 This is particularly true for high-
ly purified peptides or carbohydrates. In the absence of ad-
juvants, such killed antigens may even result in tolerance.7
Adjuvants can provide artificial signals to the immune sys-
tem to initiate the immune response. By doing so, adjuvants
minimize the number of immunizations necessary for a
good immune response. They also may decrease the amount
of antigen needed, making the vaccine more cost-effective.
Some but not all adjuvants also can shift responses toward
the more effective form or forms of immunity.
When developing a vaccine, it is essential to know what
type of immune response will provide optimal protection
and then select an adjuvant that will help induce that type
of immune response without unacceptable adverse effects.
Considerable trial and error often is needed to find a safe
and effective adjuvant for a particular pathogen in a given
species. Induction of the wrong type of immune response
actually can enhance disease pathogenesis after the animal
becomes exposed to the pathogen. Early attempts to devel-
op a vaccine against infectious peritonitis virus in cats are
an example of this response.8 Host factors also influence
the effectiveness of the adjuvant. Whereas young, healthy
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individuals sometimes can mount an effective immune re-
sponse to a less than ideal vaccine, those with poor im-
munity may not. Individuals with poor immunity include
the immunocompromised, the very old, and the very young.
By boosting immune responses, adjuvants can allow vac-
cines to be used effectively in these other groups.9
Mechanisms of Action
Most adjuvants are chemicals, microbial components, or
mammalian proteins. Despite years of research, their mech-
anism of action remains somewhat speculative.7,10 In gen-
eral, most appear to enhance antigen presentation, improve
antigen stability, or act as immunomodulators.9 A single
adjuvant may have more than 1 mechanism of action. For
example, adjuvants that help preserve the antigen’s struc-
ture can improve the effectiveness of the vaccine and also
increase its shelf life.10
Adjuvants that influence antigen presentation can affect
this complex process at numerous points. During an im-
mune response, vaccine antigens must reach secondary
lymphoid tissues, usually the lymph nodes. Most of these
antigens are carried to lymph nodes by dendritic cells.
These antigen-presenting cells (APCs), as well as macro-
phages and B cells, process the antigens and show epitopes
to T cells in major histocompatibility complex (MHC) mol-
ecules. Dendritic cells, macrophages, and B cells also pro-
vide other signals needed to initiate immunity, such as co-
stimulation by the B7 family of molecules. Any adjuvant
that can improve antigen uptake by these cells, increase
costimulatory or MHC molecules, or increase the cell’s mi-
gration to the lymph nodes can improve immunity. Some
adjuvants appear to trap the antigen at the injection site and
provide a continuing supply to local APCs. This depot ef-
fect may reduce elimination of the antigen by the liver.10
Oil emulsions such as Freund’s adjuvants can form short-
term (8–10 days) depots that are sufficient to enhance im-
munity.10 Newer microparticle adjuvants can form long-
term (1–6 months) depots and may be able to deliver pulsed
doses of antigens.10,11 Other adjuvants may work by satu-
rating Kupffer cells in the liver.10 By reducing hepatic up-
take of the antigen, such adjuvants may increase the amount
of antigen reaching the APCs. This mechanism has been
suggested for the derivatized polysaccharide adjuvants, in-
cluding high-molecular-weight sulfated dextrans and dieth-
ylaminoethyl (DEAE) dextran.10
Some adjuvants improve antigen targeting to APCs.9,10
Particulate adjuvants such as aluminum salts (alum) pro-
mote formation of aggregates; these aggregates are more
easily phagocytosed.10 Carbohydrate polymers such as man-
nan or acemannan may be able to guide antigens to APCs
by attaching to carbohydrate receptors.10 Carrier proteins
such as bovine serum albumin, keyhole limpet hemocyanin
(KLH), and diphtheria or tetanus toxoid can aid the pre-
sentation of haptens or carbohydrate antigens by recruiting
T-helper cells. Some adjuvants also appear to target the
antigen to specific compartments of the APC and influence
the induction of a CTL response. T-helper cells and CTL
responses are activated when they interact with antigens
presented in MHC II or MHC I molecules, respectively.
Although some crossing of antigens (‘‘cross-presentation’’)
occurs between pathways, antigens presented in MHC II
molecules usually come from outside the APCs and are
taken up by phagocytosis, whereas antigens presented in
MHC I molecules generally originate in the cytoplasm of
the APCs.12,13 Most adjuvants can effectively stimulate T-
helper cells and humoral immunity. Some, such as lipo-
somes, also appear to deliver antigens to pathways that lead
to the presentation in MHC I molecules and the induction
of a CTL response.9,10,14 In some cases, cross-presentation
may be important in generating CTLs.
Immunomodulation is another mechanism of action. Im-
munomodulators stimulate the immune system by altering
the cytokine network.10,11 Some adjuvants up-regulate cy-
tokines and the immune system in general. More often, ad-
juvants influence the type of immunity by enhancing some
cytokines and reducing the concentrations of others. The
cytokines interferon gamma (INF-g), interleukin-2 (IL-2),
and IL-12 are associated with T-helper cell type 1 (Th1)
responses and cell-mediated immunity (CMI). IL-4, IL-5,
IL-6, IL-13, and possibly IL-10 are associated with T-helper
type 2 (Th2) responses and humoral immunity. By shifting
the balance of these 2 sets of cytokines, adjuvants such as
saponins may stimulate CMI to an antigen that would nor-
mally induce only antibodies.9,10,15 Some immunomodula-
tory adjuvants increase the expression of costimulatory
molecules or MHC molecules on APCs, either directly or
by induction of cytokines.7,16–18
Recently, attempts have been made to fit adjuvant mech-
anisms into more general hypotheses of immune function.
According to some current hypotheses, all APCs 1st must
be activated for antigen presentation before they can initiate
immune responses. In one model, this activation is thought
to occur when pattern recognition receptors on the APCs
bind to conserved motifs in bacterial lipopolysaccharides,
sugars, or other moieties.7,19 If this hypothesis is correct,
adjuvants may act by mimicking these primitive bacterial
signals.7 In fact, many adjuvants are derivatives of bacteria
or resemble the motifs in bacterial proteins, carbohydrates,
or DNA. However, this model may not explain adjuvants
such as oil emulsions, saponins, or alum.7 According to a
2nd model (the danger model), APCs recognize endoge-
nous signals released by damaged, stressed, or dying
cells.7,19 Gallucci et al19 have found that necrotic fibroblasts
or blood vessels can act as very effective adjuvants. In ad-
dition, an influx of neutrophils can be seen after vaccination
with some adjuvants.7 The danger model, however, does not
seem to account for the effects of adjuvants such as lipo-
somes.7
Adverse Effects and Potential
Hazards of Adjuvants
When immune responses destroy invading microorgan-
isms, they cause tissue damage and result in some of the
clinical signs of illness. Similarly, as agents that enhance
immune responses, adjuvants can increase the adverse ef-
fects of the vaccine. These adverse effects are influenced
by the interactions of the specific adjuvant and antigen.9,20
Systemic, nonspecific adverse effects can include fever, ar-
thritis, uveitis, anorexia, soreness, and lethargy.9,20,21 Theo-
retically, adjuvants also may increase the probability of au-
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toimmune reactions. Overdoses of IL-2, a cytokine pro-
posed as an adjuvant, have been linked to autoimmune dis-
eases.22 Autoantibodies have been detected after
vaccination with typical canine distemper, rabies, and par-
vovirus vaccines, and a temporal association has been noted
between autoimmune hemolytic anemia and vaccination in
dogs.21 Adjuvants also may have specific adverse effects
related to their chemical nature. For example, some crude
saponin adjuvants can result in hemolysis if injected IV.23
More often, adjuvants cause local reactions including in-
flammation and, more rarely, granulomas or sterile abscess-
es. In dogs, the vaccines most often associated with local
reactions are rabies or distemper combinations; in cats, ra-
bies vaccines most often are linked to local non-neoplastic
reactions.21 Although most of these reactions are minor and
transient, 3 serious considerations emerge. First, severe in-
flammation can trap antigens at the injection site and pre-
vent them from being recognized by the immune system.22
Second, some adjuvants can result in carcass trim losses in
food animals.5,24 Certain alum-containing vaccines, for ex-
ample, can cause large granulomas in sheep.24 Granulomas
are associated particularly with depot adjuvants and can
take weeks or months to resolve.21 Finally, local inflam-
mation and granulomas after vaccination have been linked
to the development of vaccine-associated sarcomas in cats.
In the late 1980s, an alarming increase in the incidence
of vaccine-associated sarcomas in cats was observed. Cur-
rently, the incidence of these sarcomas is thought to be 1–
10 per 10,000 vaccinated cats.25 These vaccine-associated
sarcomas occur at the site of vaccination, sometimes con-
tain residual aluminum adjuvant, and have features in com-
mon with inflammatory reactions.26 They have been linked
to rabies, feline leukemia (FeLV), and other vaccines, as
well as to injections of nonvaccine products.25,27 The exact
role of antigens, adjuvants, or other factors in sarcoma de-
velopment remains to be determined, but circumstantial ev-
idence suggests that adjuvants may be involved, and the
timing of sarcoma development is suspicious. Sarcomas be-
came more common as adjuvanted vaccines became more
common. In the 1980s, the 1st FeLV vaccines had reached
the market, and modified live rabies vaccines were being
replaced by killed adjuvanted vaccines.25 Adjuvants also in-
crease inflammation, which seems to be an important risk
factor for these sarcomas.25,28–30 Apparently, some vaccines
result in inflammatory granulomas, which can, in a few
cats, develop into cancer. Aluminum adjuvants can cause
inflammation, and some authors suggest they should be
avoided in cats.31 However, this recommendation is contro-
versial. Not only have adjuvants other than aluminum been
linked to sarcomas, but tumors also can occur when vac-
cines without adjuvants are used.24,26,31
At present, no specific brands of vaccines seem to be
associated with sarcomas.25 In general, it can be difficult to
establish the incidence of rare adverse effects for any par-
ticular vaccine. Although vaccines for veterinary use must
be labeled with the adverse effects seen during premarket
testing, veterinary vaccine manufacturers are not routinely
required to update labels with postmarketing adverse effects
or to record reports of adverse effects received from vet-
erinarians.21 There may even be a disincentive to routinely
list postmarketing adverse effects, because veterinarians
may assume incorrectly that vaccines with more listed ad-
verse effects are more dangerous.21 In January 2002, the
US Department of Agriculture (USDA) proposed a new
rule that would make it mandatory for manufacturers to
keep a record of adverse effects and report them to the
USDA.32
Although these potential hazards must be appreciated,
killed vaccines generally are considered safer than modified
live vaccines, which have the potential to induce disease in
immunocompromised animals.5,6 In most instances, the ad-
verse effects of adjuvants are mild, and in general, their
benefits outweigh the hazards of their use. In specific sit-
uations such as vaccinations of cats, the benefit versus haz-
ard equation may be different and may need to be consid-
ered more carefully.
Major Types of Adjuvants
Since the discovery of the 1st adjuvants in the 1920s,
hundreds of substances with adjuvant activity have been
found. Several of the adjuvants discovered by Ramon,1
Glenny et al,3 and Freund et al4 continue to be used. Until
recently, alum compounds were the only adjuvants allowed
in vaccines for humans. Both alum and oil emulsions were
used in vaccines for animals. Freund’s original emulsion,
called Freund’s complete adjuvant (FCA), was abandoned
because of toxicity, but Freund’s incomplete adjuvant
(FIA), which contains no mycobacteria, still is used some-
times when a strong adjuvant is needed and inflammation
is not an important drawback. Recently, there has been an
upsurge of interest in new adjuvants that can induce CMI
or elicit more effective immune responses with fewer ad-
verse effects. Some vaccines contain proprietary adjuvants
whose composition cannot be made public.
Alum and Calcium Salts
Alum and calcium salts are relatively weak adjuvants that
mainly induce Th2 responses and few if any CTLs.6,10,15
Calcium salts rarely are used, but alum is widespread in
vaccines for human and veterinary use. The amount of alum
varies with the vaccine. For example, studies by Macy24
indicate that 1-year killed rabies vaccines generally contain
less alum than 3-year products. However, 3-year rabies vac-
cines sometimes are marketed as 1-year vaccines.24 Multi-
ple injections often are necessary for long-lasting immune
responses, and titers often are lower than those observed
with other adjuvants. Alum and calcium salt adjuvants once
were thought to form antigen depots, but this assumption
has been questioned.7 Alum adjuvants but not calcium salt
adjuvants also are immunomodulators.10 The safety of these
adjuvants is thought to be excellent.6,10 Serious adverse ef-
fects are rare, but allergic reactions and granulomas occa-
sionally are seen.
Oil Emulsion Adjuvants
Oil emulsion adjuvants contain a mixture of oil and aque-
ous phases, stabilized by a surfactant. Without other com-
ponents, oil-based adjuvants stimulate mainly antibody re-
sponses, but under some circumstances, water-in-oil emul-
sions may be able to activate CTLs.10,11,15,20,33 Induction of
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either Th1 or Th2 cytokines is weak to nonexistent.11,15 In
general, oil emulsions are stronger adjuvants than alum, but
at the cost of increased injection-site reactions and granu-
lomas. Traditionally, these adjuvants contained mineral oil,
but there is a risk that this oil is contaminated by carcino-
genic polycyclic aromatic hydrocarbons; consequently,
many emulsions now contain vegetable or animal oils such
as shark liver oil and squalene. Adjuvants that contain me-
tabolizable oils have a better safety record than adjuvants
based on mineral oil and tend to induce only weak inflam-
mation.10,20 Unfortunately, the increase in safety can be ac-
companied by a decrease in efficacy.20
The 3 types of oil-based adjuvants are water-in-oil emul-
sions, oil-in-water emulsions, and water-in-oil-in-water
emulsions. Water-in-oil emulsions such as FIA contain mi-
crodroplets of an aqueous phase in an oil, stabilized by a
surfactant. These adjuvants release the vaccine antigens
slowly and can give good long-term immunity.20 Injection-
site reactions are fairly common with water-in-oil adju-
vants. These emulsions also are viscous, which can make
them difficult to inject. Because of these disadvantages, wa-
ter-in-oil emulsions are not used in vaccines for humans
and companion animals. They can be found in some ru-
minant, poultry, and fish vaccines and sometimes are used
in research animals. Oil-in-water emulsions such as MF59
contain microdroplets of oil in water, stabilized by surfac-
tants. Oil-in-water emulsions free the antigen quickly and
give good short-term immunity.20 The droplets of oil may
be able to carry antigens to lymph nodes in lymphatic ves-
sels, and antigen depots may form on APCs in the lymph
nodes rather than at the injection site.33 Oil-in-water emul-
sions are less viscous and less likely to promote inflam-
mation than water-in-oil formulations.24 An influenza vac-
cine containing an oil-in-water adjuvant has been registered
for use in humans in Italy. Water-in-oil-in-water emulsions
contain microdroplets of water in an oil that is dispersed
through an aqueous phase. These adjuvants release antigens
more quickly than water-in-oil emulsions but more slowly
than oil-in-water emulsions.20 Water-in-oil-in-water emul-
sions can promote both short- and long-term immunity and
are less viscous than water-in-oil emulsions.20,24 Earlier for-
mulations were not very stable, but newer techniques ap-
pear to have overcome this problem.20
Liposomes and Archaeosomes
Liposomes are vesicles of cholesterol and phospholipids
that resemble crude cell membranes. These adjuvants can
incorporate antigens either within the lumen or in the mem-
brane. They can induce humoral immunity and, in some
cases, activate CTLs.9,10,23 Although liposomes appear to
fuse with endosomes to enter the MHC II pathway, large
quantities of some epitopes seem to spill into the cyto-
plasm.14 Liposomes have been used for years as vehicles to
deliver drugs and have a good safety record.10,14 Immuno-
modulators sometimes are added to increase their efficacy
but can also increase adverse effects. A hepatitis A vaccine
for humans with a liposomal adjuvant recently was li-
censed.
Archaeosomes, liposomes made with lipids from the Ar-
chaea, appear to be particularly good adjuvants. The Ar-
chaea are unusual bacteria-like organisms that seem to be-
long to a separate domain (or empire) that is distinct from
both bacteria and eucaryotes. The Archaea often thrive in
extreme environments and contain unusual lipids that can
form particularly stable liposomes.34 This stability may con-
tribute to the good memory responses to incorporated an-
tigens.34 Whereas lipids from species of Archaea vary in
their effectiveness, some can induce much higher titers than
alum.34 Some lipids also seem to be immunomodulators.34
Archaeosomes can induce both Th1 cytokines (INF-g) and
Th2 cytokines (IL-4), as well as cell-mediated responses to
several antigens.34 The safety of archaeosomes still is being
evaluated, but to date, no important adverse effects have
been seen.34 This lack of adverse effects is not entirely un-
expected, because some Archaea can be found in mam-
malian hosts. Methanobrevibacter smithii, one organism
used to make archaeosomes, is a normal resident in the
gastrointestinal tract of humans.
Nanoparticles and Microparticles
Nanoparticles and microparticles are tiny solid particles
made from biodegradable polymers, especially cyanoacry-
lates and poly(lactide-co-glycolide) copolymers. Nanopar-
ticles (10–1,000 nm) differ from microparticles (1–100 mm)
only in their size. The polymers used in these adjuvants
also are used as suture material, prostheses, and drug car-
riers and are thought to be nontoxic. In preliminary studies,
no serious adverse effects have been observed.35 One
unique characteristic of these adjuvants is their ability to
form a long-term depot that can release antigen for up to
several months. Mixtures of fast-releasing and slow-releas-
ing microparticles theoretically could provide both primary
and booster immunizations with 1 injection.6,10,11,15 In rats,
1 dose of tetanus toxoid with a microparticle adjuvant gave
immunity comparable to 3 doses with alum.36
Microparticles can induce CMI, including CTLs, as well
as humoral immunity.6 They usually are not immunomod-
ulators, but immunomodulators can be incorporated to im-
prove their effectiveness.11 Microparticle adjuvants can pro-
tect incorporated antigens from harsh conditions such as
low pH, bile salts, and enzyme activities. For this reason,
they may be particularly useful in oral and intranasal vac-
cines. Technical problems in manufacture can be a disad-
vantage because the encapsulation process may alter anti-
gens and decrease their ability to stimulate the immune sys-
tem. However, new techniques and types of particles may
circumvent this problem.35 Nanoparticles and microparticles
are being tested in companion animals, including horses, as
well as in cattle, swine, and fish.20
Saponins
Saponins are complex chemical adjuvants extracted from
plants, most often the tree Quillaia saponaria. The crude
extract from this tree is called saponin. Quil A and Spi-
kosidea are partially purified mixtures, and QS21 and IS-
COPREP 703b are defined fractions. Quil A is widely used
in veterinary medicine and has been used in vaccines for
cattle, pigs, horses, dogs, and cats, including equine influ-
enza virus, canine parvovirus, and FeLV vaccines.24 QS21
is used in an FeLV vaccine and a canine Lyme disease
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vaccine. Saponins are immunomodulators and can induce
strong Th1 and Th2 responses as well as CTLs.9,10,15 They
generally are thought to be safe, but their relative safety
may depend on the route of administration, the species, and
the specific saponin.10,23,37 IV injections of less purified frac-
tions can result in toxicity, probably due to hemolysis.23
Injections of free Quil A are well tolerated in sheep and
cattle, but some toxicity has been reported in cats.37 Local
inflammatory reactions occur with free Quil A but can be
suppressed without loss of adjuvant activity when it is com-
bined with cholesterol-containing liposomes.23 Purified sa-
ponin fractions have a much lower toxicity than Quil A and
are being considered for vaccines in humans.10,23,37
Immune-Stimulating Complexes
Immune-stimulating complexes (ISCOMs) are cagelike
structures that contain saponins, cholesterol, and phospho-
lipids. In veterinary vaccines, the saponin sometimes is
Quil A, but more purified fractions are used in vaccines for
humans. ISCOMs are immunomodulators.7,18 They can in-
duce Th1 reactions and CTLs as well as concurrent Th2
responses in some circumstances.37,38 ISCOMs can be ef-
fective adjuvants in cats, dogs, cattle, horses, pigs, sheep,
turkeys, rabbits, guinea pigs, and mice.18,37 They have been
used with more than 20 viral, bacterial, and parasitic path-
ogens and are found in experimental bovine viral diarrhea
virus, bovine herpes virus type 1, rinderpest, FeLV, pseu-
dorabies, and canine distemper vaccines.18,23,38–44 An equine
influenza vaccine with an ISCOM adjuvant currently is
marketed for horses in Europe. ISCOMs also are being test-
ed for use in vaccines for humans. ISCOMs sometimes
have toxic effects in rats and mice, but few adverse effects
have been observed in species of veterinary importance.10,37
Most likely, this observation is due to a dose effect.
Nonionic Block Copolymers
Nonionic block copolymers are synthetic adjuvants com-
posed of blocks of hydrophobic polyoxypropylene flanked
by blocks of polyoxyethylene. Nonionic block copolymers
are used in shampoos, mouthwashes, and cosmetics gen-
erally and are regarded as safe.45 As adjuvants, these chem-
icals can enhance humoral immunity to a number of viral,
bacterial, and parasitic antigens.45 They may induce CTLs.45
Most often, nonionic block copolymers are used in an aque-
ous buffer and in oil-in-water or water-in-oil emulsions.
They are found in combination adjuvants such as Syntex
adjuvant formulation (SAF)c and IDEC antigen formula-
tiond emulsions. These adjuvants may act as immunomod-
ulators, but they mainly appear to improve antigen presen-
tation.10 They are not biodegradable and can cause local
reactions.10
Derivatized Polysaccharides
High-molecular-weight sulfated dextrans and DEAE-
dextran sometimes are used as veterinary adjuvants. They
also have been suggested for use in vaccines for humans.
Derivatized polysaccharides may work by saturating Kupf-
fer cells in the liver and preventing antigen degradation.10
Carrier Proteins
Protein carriers can be linked to antigens to improve their
immunogenicity. Such carriers are especially effective for
haptens and carbohydrate antigens, which are poorly im-
munogenic, especially in the young. Carriers that have been
used include diphtheria or tetanus toxoid, KLH, and bovine
serum albumin. The toxoids are commonly used for car-
bohydrate vaccines in humans.6 Peptides that have been
successfully conjugated with KLH to induce an immune
response include fragments from bovine papillomavirus-4,
tick-borne encephalitis virus, and porcine parvovirus.46
Bacterial Products and Their Derivatives
Historically, whole heat-killed bacterial preparations
sometimes were used as crude adjuvants. The most famous
example is the use of mycobacteria in FCA. More recently,
Siwicki et al47 found that heat-killed lyophilized prepara-
tions of Propionibacterium avidum KP-40 could enhance
the antibody response to a coadministered antigen. For use
in modern vaccines, such bacterial preparations must be
further refined and often detoxified.
Muramyl dipeptide (MDP) is the active component of an
immunomodulatory peptidoglycan from mycobacteria.
MDP has important adverse effects, including fever, arthri-
tis, and uveitis, but less toxic derivatives have been
made.6,33 The hydrophilic derivatives (eg, threonyl-MDP,
murametide, murabutide, nor-MDP, and N-acetylglucosa-
minyl-MDP) mainly induce Th2 responses.10 Lipophilic de-
rivatives (eg, MTP-PE [muramyl tripeptide phosphatidyl
ethanolamine]) tend to induce Th1 reactions.10 MDP deriv-
atives often are incorporated into liposomes or into water-
in-oil and oil-in-water emulsions. Threonyl-MDP also has
been used in experimental FeLV vaccines.24
Bacterial toxins also can act as adjuvants. Several aden-
osine diphosphate (ADP)-ribosylating toxins are being con-
sidered for mucosal or transcutaneous use. The 2 that have
been tested most extensively are cholera toxin and Esche-
richia coli heat-labile exotoxin (LT). These 2 toxins are
promising mucosal adjuvants in some animal models and
have been proposed for use in humans.10,11,15 They appear
to induce strong humoral responses as well as CTLs.11,17
For mucosal use, both LT and cholera toxins must be mu-
tated to less toxic forms, but Glenn et al48 have discovered
that the virulent native toxins are effective adjuvants for
transcutaneous immunization. When intact cholera toxin
was applied to the skin of mice, immune responses were
induced to coadministered antigens with no major adverse
effects. Secondary humoral immune responses have been
seen in these experiments, and mice were protected against
systemic challenge.
Lipopolysaccharide components also can be effective ad-
juvants. Lipid A and its derivative, 49 monophosphoryl lip-
id A (MPL), are immunomodulators that can induce strong
Th1 responses.10 Although lipid A is too toxic to use as an
adjuvant, MPL from Salmonella minnesota is being consid-
ered for use in vaccines in humans.
Gliding bacterial adjuvant (GBA) is a particularly inter-
esting new adjuvant. GBA is a large polymer of amino
sugars from the bacterial genus Cytophaga. This polysac-
charide can stimulate cytokine release in cats, mice, and
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humans and appears to be an effective, safe adjuvant.49,50
GBA seems to be most effective when it is combined with
other adjuvants such as alum or an oil emulsion.49,50 In cats,
GBA combined with an oil-based adjuvant promoted mark-
edly higher antibody responses than either alum or Titer-
max,e a potent water-in-oil adjuvant containing copolymer
CRL-8941.50
Bacterial DNA can act as an adjuvant and induce cyto-
kine release. CpG oligonucleotides are adjuvants that mimic
a bacterial DNA motif that is underrepresented in vertebrate
DNA. These oligonucleotides contain a central unmethy-
lated CpG dinucleotide, ideally flanked by two 59 purines
(preferably GpA) and two 39 pyrimidines (preferably TpC
or TpT). This motif is 3–20 times more common in bac-
terial and viral DNA than in mammalian DNA.51,52 CpG
oligonucleotides are immunomodulators, can induce anti-
bodies, and appear to be particularly effective in shifting
immunity toward Th1 responses.51–53 Some authors believe
that it may be possible to control the balance between hu-
moral immunity and CMI by titering the concentration of
a CpG adjuvant.53 The safety of these adjuvants remains to
be determined. Although low doses appear to be safe in
some studies, repeated high doses of CpG oligonucleotides
can induce splenomegaly in mice, and bacterial DNA can
cause cytokine release and fatal shock.51,54,55 It may be pos-
sible to reduce these adverse effects by incorporating CpG
sequences into the sequence of DNA vaccines or by teth-
ering the oligonucleotides to the antigen.53
Cytokines
Cytokine proteins and genes themselves are being con-
sidered vaccine adjuvants. The specific effects vary with
the cytokine: some enhance the activity of defined immune
cells, whereas others act as general activators. Cytokines
also induce other cytokines, and this property can make the
effects of a specific cytokine difficult to predict. Cytokines
being considered adjuvants include INF-g, IL-1, IL-2, gran-
ulocyte-macrophage colony stimulating factor, and IL-12.9
In a limited number of experiments, recombinant IL-1 and
IL-2 have been promising as adjuvants in sheep and cattle
when combined with other adjuvants.56 Currently, there is
special interest in IL-12, which appears to shift the immune
response toward Th1 responses. In cats, IL-12 was an ef-
fective adjuvant for an experimental feline immunodefi-
ciency virus subunit vaccine, and IL-12 combined with IL-
18 was effective in an FeLV DNA vaccine.57,58 Although
exogenous cytokines seem to shift Th1 or Th2 responses in
some trials, they do not in others.22 A possible explanation
is that certain antigens induce such strong humoral respons-
es that the adjuvant cannot influence the result.
Several problems remain before cytokines can be incor-
porated routinely into vaccines. These proteins often are
species-specific, and only a limited number of cytokines
have been cloned from species of veterinary importance.
Furthermore, work with inbred mice does not always trans-
late well to outbred species of veterinary importance. For
example, IL-10 in mice can shift the balance of Th1 and
Th2 responses, but in cattle, IL-10 does not have the same
effect.22 Some cytokines may not be stable enough for vac-
cines. Toxicity also is a concern. Most cytokines are made
only in small quantities during the immune response and
mainly act locally. When large amounts enter the systemic
circulation, the potential for severe shock and death, or less
severe adverse effects, exists. Some cytokines also may
promote autoimmunity, and overdoses of IL-2 have been
linked to autoimmune diseases.22 An optimal dose can be
found for some cytokines, with smaller doses ineffective
and larger doses toxic or even immunosuppressive.22 For
other cytokines, the effective dose may be similar to the
toxic dose. To overcome some of these difficulties, modi-
fied, less toxic derivatives of IL-1 and IL-6 are being de-
veloped.22 An alternative approach is to decrease toxicity
by means of cytokine inducers such as avridine, GBA, and
MPL.10,22,49,50
Complement Derivatives
Components of the mammalian complement system also
appear to be promising adjuvants for inducing antibody re-
sponses. Fragments of these proteins bind foreign antigens,
tagging them for the receptors of antibodies and immune
cells. The fragment C3d may be a particularly useful ad-
juvant. In one study, attaching 3 C3d molecules to an an-
tigen increased its immunogenicity 1,000-fold.59 Antigens
that have been successfully modified by C3d include the
influenza virus hemagglutinin, anti-idiotype antibodies, and
capsular polysaccharides.60–62 The fragment C3b also has
shown adjuvant activity.63 One potential concern with com-
plement adjuvants is the possibility that they might activate
B cells nonspecifically and induce autoimmunity.62 To date,
this does not seem to have occurred, and the antibody re-
sponse appears to be specific to the antigen.62
Combined Adjuvants
Although some adjuvants such as alum commonly are
used alone, many well-known vaccine adjuvants are com-
bination adjuvants. FCA is a water-in-oil emulsion with
mycobacteria. The Ciba-Geigy adjuvant formulation is a
modified, less toxic version of Freund’s adjuvant that in-
corporates a metabolizable oil (squalene) and nor-MDP.10
SAF contains a nonionic block copolymer (L121) with
threonyl-MDP in squalene, and Ribi DETOX adjuvantf con-
sists of MPL and cell wall skeleton in squalene.33,64
The result of combining adjuvants depends on the mech-
anism of action and toxicity of each individual component.
Combinations may be better, similar to, or worse than the
individual components. Weeratna et al65 compared adjuvant
strength in mice immunized IM with hepatitis B antigen.
When single adjuvants were tested, the most effective ad-
juvants were FCA and Titermax Gold (a water-in-oil ad-
juvant containing the copolymer CRL-8300), but these 2
adjuvants administered singly also resulted in the most
damage to injected muscles. FIA, CpG oligonucleotides, or
MPL induced lower titers. FIA caused moderate muscle
damage, and CpG oligonucleotides or MPL resulted in mild
damage. The least effective adjuvant, with the least amount
of damage, was alum. Combining CpG oligonucleotides
with alum increased antibody titers to those seen with FCA
with minimal muscle damage. CpG oligonucleotides and
FIA also resulted in high titers but more muscle damage.
Other combinations did not improve efficacy: CpG oligo-
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nucleotides and MPL were no more effective than either
adjuvant alone. Finally, combining MPL and alum actually
reduced the immune response, possibly from toxic effects
or interference between their mechanisms of action.
Adjuvants for Mucosal Vaccines
Mucosal vaccines can have marked advantages over sys-
temic vaccines. The benefits may include decreased adverse
effects, easier administration, and induction of immunity at
the natural point of entry for a pathogen. The choice of
adjuvant can be an important factor in the success of these
vaccines. The adjuvant must be able to survive harsh con-
ditions, particularly in the gastrointestinal tract. It also is
helpful if the adjuvant can protect the antigen and deliver
it to local immune tissues. Furthermore, the adjuvant-anti-
gen combination optimally should induce IgA antibodies
on mucosal surfaces as well as systemic immune responses.
Candidate adjuvants for mucosal vaccines include lipo-
somes, microparticles and nanoparticles, cytokines, IS-
COMs, monophosphoryl lipid A, CpG, and detoxified
ADP-ribosylating toxins.6,11,23,38,66,67 Microparticles and
nanoparticles are particularly interesting because they may
be uniquely able to protect antigens from low pH, bile salts,
and enzyme activities.35 Adjuvants that are able to induce
systemic Th1 or CTL responses as well as systemic and
mucosal antibodies include microparticles and nanoparti-
cles, ISCOMs, and monophosphoryl lipid A.6,10,11,18
Conclusion
Interest in alternatives to oil emulsions and alum has led
to the increasing availability of new adjuvants over the last
decade. The new generation of adjuvants represents a great
diversity of chemical compounds with different mecha-
nisms of action and different potential adverse effects. One
goal in adjuvant research has been to find more effective
adjuvants with fewer adverse effects. In addition, interest
in fine-tuning immune responses has resulted in adjuvants
that direct the immune response toward specific types of
immunity. Currently, a number of new adjuvants are in clin-
ical trials or available in new vaccines. To select an adju-
vant for a vaccine, it must be understood that the best ad-
juvant is not always the same for all antigens and situations.
The optimal adjuvant depends on the animal species, spe-
cific pathogen, vaccine antigen, route of immunization, and
type of immunity needed. This complexity can be illustrat-
ed by the vaccination of cattle against Streptococcus bovis
and Lactobacillus spp. to decrease lactic acidosis.68 DEAE-
dextran with mineral oil, Quil A, and alum all proved better
adjuvants than FCA in this situation. Good adjuvants for
vaccines against extracellular bacteria will not necessarily
be good adjuvants for intracellular pathogens. Mucosal ad-
juvants may require specific characteristics. Often, adju-
vants may need to be tailored to the species as well. Cats
appear to be particularly sensitive to inflammation and sus-
ceptible to vaccine-induced sarcomas. In this species, a
higher priority may need to be placed on less reactive ad-
juvants. Given these considerations, it should be increas-
ingly possible to design and select adjuvants tailored to the
specific needs of the antigen, species, and situation.
Footnotes
a Spikoside, Iscotec AB, Stockholm, Sweden
b ISCOPREP 703, Iscotec AB, Stockholm, Sweden
c SAF, Biocine Co, Emeryville, CA
d Antigen formulation, IDEC Pharmaceutical Corp, San Diego, CA
e Titermax adjuvant, CytRx Corp, Norcross, GA
f DETOX adjuvant, Ribi Immunochem Research, Hamilton, MT
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